Introduction {#S1}
============

Diabetes affects approximately 170 million people worldwide, including 20.8 million in the US, and these numbers are projected to double by 2030 ([@R10]). In patients with diabetes, impaired angiogenesis and diminished granulation-tissue formation often couple with other factors, such as decreases in cell and growth-factor response, to reduce peripheral blood flow, which can retard wound healing and lead to the development of nonhealing foot ulcers ([@R10]; [@R14]; [@R23]). Non-healing ulcers affect 15% of people with diabetes and are a leading cause of amputation ([@R10]; [@R14]; [@R23]; [@R31]). Inflammation is a key component of the wound-healing response and mediates many of the effects induced by chemokines ([@R29]) such as stromal-cell--derived factor 1 (SDF-1), which binds to CXC chemokine receptor 4 (CXCR4) and regulates both inflammation and cell migration ([@R34]). Thus, interactions between SDF-1 and CXCR4 contribute to cutaneous wound healing ([@R5]), but the mechanisms involved remain incompletely characterized. Recent experiments conducted in our laboratory indicate that administration of the CXCR4 antagonist AMD3100 promotes neovascularization after myocardial infarction by mobilizing endothelial progenitor cells (EPCs) from the bone marrow and by enhancing EPC recruitment to the sites of ischemia ([@R24]). Here, we investigated whether AMD3100 promotes cutaneous wound healing through a similar mechanism.

Results {#S2}
=======

Topical AMD3100 accelerates wound healing in diabetic mice {#S3}
----------------------------------------------------------

Full thickness excisional skin wounds were created on the backs of db/db mice, treated with AMD3100 or saline, and examined 0, 7, and 14 days later ([Figure 1A](#F1){ref-type="fig"}). On day 14, the extent of wound closure was significantly greater (*P*\<0.0001) in mice treated with AMD3100 (86.97±2.55%) than in saline-treated mice (33.07±1.82%) ([Figure 1B](#F1){ref-type="fig"}), and histological scores were significantly higher for AMD3100-treated wounds than for wounds treated with saline ([Figures 1C-E](#F1){ref-type="fig"}) (epithelialization: AMD3100, 4.250±0.250, saline, 2.000±0.408, *P*\<0.005; granulation: AMD3100, 4.750±0.479, saline, 2.250±0.479, *P*\<0.01; inflammation: AMD3100, 3.750±0.250, saline, 2.500±0.289; *P*\<0.05) ([Figures 1C-E](#F1){ref-type="fig"}); inflammation scores were also significantly higher for AMD3100-treated wounds on day 7 (AMD3100, 3.500±0.289, saline, 1.500±0.289, *P*\<0.005). Thick granulation tissue, extensive re-epithelialization, and persistent inflammation-related acanthosis were observed on the surface of AMD3100-treated wounds, and functional, erythrocyte-containing blood vessels were prevalent in the deeper dermis, whereas saline-treated wounds exhibited a thin layer of granulation tissue and fewer functional blood vessels ([Figure 1F](#F1){ref-type="fig"}).

AMD3100 enhances collagen formation at the wound site {#S4}
-----------------------------------------------------

Because collagen formation is a crucial component of wound healing, sections of wound tissue were stained to identify collagen in the granulation tissue (Masson\'s Trichrome staining) and to assess collagen-fiber formation at the wound center (picosirius red staining), which is the last region of the wound to heal. Fourteen days after wounding and treatment, collagen fibers were observed throughout the granulation tissue in AMD3100-treated wounds, but were restricted primarily to the edges of saline-treated wounds ([Figure 2A](#F2){ref-type="fig"}). The collagen fibers in AMD3100-treated wounds were heterogeneous and appeared to contain a cellular (perhaps fibroblast) component, which suggests that the fibers were newly formed; AMD3100-treated wounds also displayed evidence of persistent acanthosis. At the wound center, collagen fibers were significantly more common (*P*\<0.05) in AMD3100-treated wounds (9.210±1.883% of image area) than in wounds treated with saline (3.901±0.174% of image area) ([Figure 2B](#F2){ref-type="fig"}).

AMD3100 increases capillary density, the formation of smooth muscle--containing vessels, and monocyte/macrophage infiltration {#S5}
-----------------------------------------------------------------------------------------------------------------------------

Fourteen days after wounding and treatment, capillary density was significantly higher (*P*\<0.01) in AMD3100-treated wounds (3.81±0.54% of image area) than in wounds treated with saline (1.16±0.18% of image area) ([Figure 2C, D](#F2){ref-type="fig"}), and smooth muscle--containing vessel-like structures were more common in the dermis of the AMD3100-treatment group (AMD3100: 52.2±8.0 vessels/high-power field \[HPF\], saline: 9.8±1.6 vessels/HPF; *P*\<0.001) ([Figure 2C, E](#F2){ref-type="fig"}). Cells stained positively for the monocyte/macrophage-specific marker CD68 ([Figure 2F](#F2){ref-type="fig"}) were significantly more prevalent in wounds treated with AMD3100 than in saline-treated wounds on day 7 (AMD3100: 164.250±26.544 cells/HPF, saline: 28.750±5.735 cells/HPF; *P*\<0.01) ([Figure 2G](#F2){ref-type="fig"}), and real-time RT-PCR analyses of CD68 mRNA expression yielded similar results: treatment with AMD3100 was associated with significantly greater CD68 mRNA expression on day 7 (AMD3100: 230.163±18.913, saline: 69.912±8.638; *P*\<0.0001) but not on day 14 ([Figure 3A](#F3){ref-type="fig"}).

AMD3100 upregulates SDF-1α and platelet-derived growth factor B mRNA expression at the wound site {#S6}
-------------------------------------------------------------------------------------------------

Real-time RT-PCR analyses of the expression of SDF-1α and platelet-derived growth factor (PDGF)-B, which are known to enhance progenitor-cell homing, indicated that both factors were expressed at significantly higher levels in wounds treated with AMD3100 than in saline-treated wounds on day 7 (SDF-1α: AMD3100, 107.160±24.067; saline, 28.533±1.639; *P*\<0.01. PDGF-B: AMD3100, 5.427±0.626; saline, 2.840±0.319; *P*\<0.001) but not on day 14 ([Figure 3B, C](#F3){ref-type="fig"}).

AMD3100 mobilizes cells from the bone marrow to the peripheral circulation {#S7}
--------------------------------------------------------------------------

To determine whether the accelerated healing observed after AMD3100 treatment was associated with enhanced mobilization of cells from the bone marrow, the number of EPCs and macrophages in the peripheral blood was assessed 7 days after wounding and treatment. EPCs were identified by DiI-labeled acetylated low density lipoprotein (DiI-acLDL) uptake and Bandeiraea simplicifolia lectin 1( BS1-lectin) staining, whereas macrophages were identified via CD68 expression; isolectin B4 is a marker for macrophage activation ([@R20]; [@R26]; [@R40]; [@R47]), so cells stained positively for both isolectin B4 and CD68 expression were considered activated macrophages ([Figure 4A](#F4){ref-type="fig"}). All three cell types were significantly more common (*P*\<0.0001) in mice treated with AMD3100 (EPCs: 48.400±2.948 cells/HPF; macrophages: 27.600±0.909 cells/HPF, activated macrophages: 12.600±1.462 cells/HPF) than in the saline-treatment group (EPCs: 9.500±1.067 cells/HPF, macrophages: 7.000±0.816 cells/HPF, activated macrophages: 2.300±0.667 cells/HPF) ([Figure 4B](#F4){ref-type="fig"}).

AMD3100 promotes the migration and proliferation of diabetic mouse primary dermal fibroblasts and the proliferative and phagocytosis activity of macrophages {#S8}
------------------------------------------------------------------------------------------------------------------------------------------------------------

The cellular mechanisms responsible for AMD3100-enhanced wound healing were investigated by evaluating the migration and proliferation of db/db mouse primary dermal fibroblasts in 5 mM and 25 mM D-glucose; measurements were repeated in 25 mM D-mannitol to serve as an osmotic control for the high-glucose condition. Fibroblasts migrated toward 2 μg/mL AMD3100 under all conditions ([Figure 5A, B](#F5){ref-type="fig"}). In cells cultured at the high-glucose concentration, 2 μg/mL AMD3100 significantly promoted fibroblast proliferation ([Figure 5C](#F5){ref-type="fig"}), but a higher AMD3100 concentration (10 μg/mL) was required to significantly stimulate proliferation under the low-glucose or osmotic-control conditions. AMD3100 also promoted the proliferation (2 μg/mL AMD3100: 0.307±0.013 OD, 0 μg/mL AMD3100: 0.191±0.007 OD; *P*\<0.0001) and phagocytosis activity (2 μg/mL AMD3100: 0.487±0.019 OD, 0 μg/mL AMD3100: 0.351±0.019 OD; *P*\<0.01) of macrophages, but did not significantly affect EPC proliferation ([Figure 5D](#F5){ref-type="fig"}).

AMD3100 enhances fibroblast migration and proliferation in the absence of CXCR4 protein expression {#S9}
--------------------------------------------------------------------------------------------------

AMD3100 is a CXCR4 antagonist, and CXCR4 is expressed in murine db/db fibroblasts; however, human fibroblasts do not express CXCR4 ([@R5]). Thus, we investigated whether CXCR4 is required for the AMD3100-induced enhancement of fibroblast migration and proliferation by performing experiments with NIH 3T3 fibroblasts, which express nearly undetectable amounts of CXCR4 mRNA (3T3: 0.001±0.0001, db/db: 0.047±0.005; *P*\<0.0001). The migratory response of 3T3 fibroblasts was significantly enhanced by AMD3100 (2 μg/mL AMD3100: 250.267±18.032 cells/HPF, 0 μg/mL AMD3100: 112.167±17.559 cells/HPF; *P*\<0.0001) ([Figure 6A](#F6){ref-type="fig"}), and AMD3100 also promoted 3T3 fibroblast proliferation (2 μg/mL AMD3100: 0.337±0.015 OD, 0 μg/mL AMD3100: 0.256±0.008 OD; *P*\<0.001) ([Figure 6B](#F6){ref-type="fig"}). To characterize the molecular mechanisms responsible for the AMD3100-induced enhancement of 3T3 fibroblast activity, we measured the mRNA expression of a panel of candidate factors. After 12 hours in culture, treatment with AMD3100 was associated with significant upregulation of SDF-1α (2 μg/mL AMD3100: 104.594±2.234, 0 μg/mL AMD3100: 70.058±4.105; *P*\<0.0001), PDGF-B (2 μg/mL AMD3100: 0.045±0.001, 0 μg/mL AMD3100: 0.014±0.003; *P*\<0.0001), and MCP-1 (2 μg/mL AMD3100: 12.528±1.819, 0 μg/mL AMD3100: 6.645±2.121; *P*\<0.05) mRNA expression ([Figure 6C](#F6){ref-type="fig"}).

Discussion {#S10}
==========

Therapeutic strategies that block the interaction between CXCR4 and SDF-1 are promising treatments for a variety of clinical applications. CXCR4 was first identified as a co-receptor for cellular entry of the human immunodefficiency virus (HIV) ([@R7]), and more recent evidence indicates that CXCR4 has a role in stem-cell trafficking, vascular growth, and cancer metastasis ([@R30]; [@R32]; [@R41]; [@R44]; [@R49]). AMD3100 was the first CXCR4 antagonist to enter clinical trials, and although it failed as an anti-HIV drug, phase 3 trials for its use in stem-cell mobilization have recently been completed ([@R1]).

Angiogenesis is a crucial component of wound healing ([@R10]; [@R14]; [@R37]); however, peripheral blood flow is often impaired in patients with diabetes, which can retard wound healing and lead to the development of nonhealing ulcers and subsequent amputation ([@R10]; [@R14]; [@R23]; [@R31]). Current treatments for nonhealing ulcers often combine off-loading ([@R8]) with the administration of growth factors (e.g., PDGF-BB ([@R39])) and/or cell-based approaches delivered in an absorbable mesh (fibroblasts) ([@R27]) or in type 1 collagen (fibroblasts and keratinocytes) ([@R9]). Here, we investigated whether the angiogenic effects associated with AMD3100 administration could improve cutaneous wound healing in genetically diabetic mice, which, like patients with diabetes, display impairments in wound healing, granulation tissue formation, and angiogenesis ([@R19]; [@R48]). However, mouse models of chronic wound repair do not always replicate the human experience, so our findings must be interpreted with caution.

Our results indicate that topical application of AMD3100 accelerates wound healing in diabetic mice. Wound closure was 2.5-fold more complete 14 days after treatment with AMD3100 than after saline treatment and was accompanied by significantly higher histological scores, notably thicker granulation tissue (perhaps associated with acanthosis), and improved collagen deposition and fiber formation. AMD3100 treatment was also associated with greater macrophage accumulation and PDGF-B expression at the wound site. Because PDGF-B promotes macrophage activation, fibroblast proliferation, and the recruitment of both cell types ([@R37]), topical AMD3100 treatment likely enhances wound healing by inducing a variety of effects in both macrophages and fibroblasts. However, not all of these effects can be attributed to CXCR4 antagonism, because AMD3100 stimulated the migration and proliferation of 3T3 fibroblasts, which express little, if any, CXCR4.

Capillaries and smooth muscle--containing vessels were more prevalent in AMD3100-treated wounds than in wounds treated with saline, suggesting that AMD3100 promotes neovascularization (i.e., the development of new blood vessels) and vascular remodeling (i.e., arteriogenesis). Neovascularization occurs via two processes: angiogenesis, the proliferation and migration of pre-existing, fully-differentiated endothelial cells in nearby vessels; and vasculogenesis, the *de-novo* assembly of new blood vessels ([@R15]; [@R21]). Historically, vasculogenesis was believed to occur only during embryogenesis; however, the results from more recent experiments indicate that EPCs in the peripheral blood participate in postnatal vasculogenesis by incorporating into new vessels and by expressing a variety of growth factors in ischemic tissue ([@R2]; [@R21]; [@R24]; [@R46]). In the absence of ischemia, interactions between CXCR4 and SDF-1α sequester EPCs in the bone marrow, but disruption of the SDF-1α/CXCR4 axis with AMD3100 mobilizes these (and other) cells to the peripheral circulation ([@R11]; [@R36]), as evidenced by the elevated peripheral-blood EPC and macrophage counts observed in mice treated with topical AMD3100.

In both patients and animal models, diabetes is associated with low circulating EPC counts ([@R12]; [@R13]; [@R17]; [@R35]; [@R43]; [@R45]) and a loss of SDF-1α expression in ischemic tissue, which impairs the recruitment of circulating EPCs to the injury site ([@R10]; [@R17]). Impaired EPC recruitment in genetically diabetic mice ([@R17]), streptozotocin-induced diabetic mice ([@R38]), and in nude mice ([@R42]) can be circumvented by administering human EPCs directly to the cutaneous wound, and both EPC mobilization and recruitment can be enhanced by topical application of SDF-1α to the wounds of db/db mice ([@R17]). Here, we demonstrated that topical AMD3100 increases both peripheral-blood EPC counts and the expression of SDF-1α at the wound site, so the improved neovascularization and wound healing associated with AMD3100 treatment likely evolved, at least in part, via enhanced EPC recruitment. Topical application of VEGF ([@R16]), sonic hedgehog ([@R4]), or dibutyryl cAMP ([@R3]) to cutaneous wounds has also been shown to increase neovascularization by increasing EPC mobilization and/or recruitment.

Dermal fibroblasts are among the primary targets of PDGF during cutaneous wound healing ([@R37]). The two PDGF receptor (PDGFR) subtypes, PDGFR-α and PDGFR-β, have distinct roles in development, and PDGFR-β is an important mediator for the contribution of dermal fibroblasts to wound healing ([@R18]). The role of the PDGF-B/PDGFR-β system in adult tissues has been difficult to characterize, because homozygous disruption of either PDGF-B or PDGFR-β in mice results in perinatal death ([@R18]); however, blockade of PDGF-BB signaling delays tumor growth ([@R6]) and cutaneous wound healing ([@R33]). Collectively, these observations suggest that AMD3100 accelerates wound healing primarily by increasing fibroblast activity and noevascularization, although enhancements in keratinocyte activity and re-epithelialization cannot be excluded.

In conclusion, the results from our investigation indicate that a single topical application of AMD3100 promotes cutaneous wound healing and neovascularization in diabetic mice, and that these effects are likely induced both directly, through enhanced fibroblast and macrophage activity, and indirectly, through the stimulation of cytokine production and the mobilization of progenitor cells from the bone marrow into the peripheral circulation. Our findings must be interpretted with caution, however, because the results from mouse models of chronic wound repair do not always predict patient response. Future investigations are warranted to determine the potential clinical utility of this compound for the treatment of nonhealing skin ulcers in patients with diabetes or microvascular disorders.

Materials and Methods {#S11}
=====================

Animals, wound model, and treatment {#S12}
-----------------------------------

The Institutional Animal Care and Use Committee of Northwestern University approved all described studies. Experiments were performed with 10- to 12-week-old female, genetically diabetic, C57BLKS/J-m^+/+^*Lepr*^db^ (db/db) mice and their C57BLKS/6J wild-type littermates (The Jackson Laboratories, Bar Harbor, ME, USA). Cutaneous wounds were created as described previously ([@R3]; [@R4]; [@R19]; [@R28]) and as summarized in the [Supplemental Methods](#SD1){ref-type="supplementary-material"}. Immediately after wounding, 6 mg/kg AMD3100 octahydrochloride (Sigma-Aldrich Co., St. Louis, MO, USA) in 30 μL saline or saline alone was topically applied to the wound bed, and then a semipermeable transparent dressing was placed over the wound, secured to the surrounding skin and muscle with 6-0 Prolene surtures, and left in place until subsequent evaluations were performed (i.e., for up to 14 days after wounding); suture use was minimized and did not interfere with wound contraction. The AMD3100 dose was determined in preliminary experiments: 2-, 6-, and 10-mg doses were tested, and the 6-mg dose was the minimum required to achieve the greatest acceleration of wound healing.

Wound closure {#S13}
-------------

Wounds were photographed with a digital camera (Nikon Coolpix 995; Nikon Inc., Melville, NY, USA), then images were analyzed by tracing the wound margin with a fine-resolution computer mouse and calculating the enclosed pixel area with National Institute of Health (NIH) Image software ([@R3]; [@R4]; [@R19]; [@R28]). Measurements were performed in duplicate, and the percentage of wound closure was calculated by using the following equation: $$\text{Wound\ closure}\left( \% \right) = \frac{\text{Wound\ area\ on\ day}\; 0 - \text{Wound\ area\ on\ the\ indicated\ day}}{\text{Wound\ area\ on\ day}\; 0} \times 100\%$$

Histological scores {#S14}
-------------------

Wound tissue was harvested, fixed in 100% methanol, processed by standard methods, and cut into 5-μm sections; then, the sections were paraffin-embedded, stained with hematoxylin and eosin, and viewed with an Olympus VANOX AHBT3 (Olympus America Inc, Center Valley, PA, USA). Epithelialization, granulation, and inflammation were rated from 1 (little or none) to 5 (extensive or severe) by investigators who were blind to treatment as described previously ([@R3]; [@R4]; [@R19]; [@R28]) with modifications.

Collagen formation {#S15}
------------------

Collagen formation was evaluated as described previously ([@R3]; [@R4]) in 5-μm, paraffin-embedded sections of wound tissue that were stained with Masson trichrome. To evaluate collagen fiber formation at the wound center, sections were stained with picosirius red and viewed under polarized light to accentuate the birefringence of collagen fibers ([@R25]). Fiber formation was quantified as the percentage of the digitized image that fluoresced red (mature fibers) or yellow-green (immature fibers).

Wound vascularity {#S16}
-----------------

Vasculature in the healing wound was evaluated as described previously ([@R3]; [@R4]). Wounds were harvested, sectioned, and then stained with fluorescein isothiocyanate (FITC)--conjugated BS-1 lectin and with mouse monoclonal alkaline-phosphatase anti-smooth-muscle α-actin (αSMA) (1:100) (Sigma-Aldrich Co.). Nuclei were counterstained with 4\',6-diamidino-2-phenylindole (DAPI). The sections were viewed with a Carl Zeiss Axio Observer.D1 (Carl Zeiss MicroImaging Inc, Thornwood, NY, USA) (50× magnification) and digitally photographed. Capillary density was quantified as the percentage of the image area that fluoresced positively for FITC-BS1 lectin, and smooth muscle--containing vessels were identified by positive staining for both FITC-BS1 lectin and αSMA. Assessments were performed in 3 sections, 4 HPFs per section.

Infiltration of monocytes/macrophages {#S17}
-------------------------------------

Paraffin-embedded, 5-μm sections of wound tissue were sequentially stained with rat monoclonal anti-mouse CD68 primary antibodies (AbD Serotec, Raleigh, NC, USA) and Alexa Fluor 555 goat anti-rat IgG secondary antibodies (Invitrogen Corporation, Carlsbad, CA, USA). Secondary staining with normal rat IgG was performed as a negative control, and nuclei were counterstained with DAPI. Sections were viewed with a Carl Zeiss Axio Observer.D1 and Image J™ software (NIH, USA) (to enable adjustment of the threshold of fluorescence intensity); cells located at the wound center and stained positively for CD68 expression were counted in 3 sections, 4 HPFs per section.

Mobilization of bone marrow--derived cells {#S18}
------------------------------------------

Circulating EPC levels were evaluated as described previously ([@R22]). Mononuclear cells were isolated from 500 μL of peripheral blood via gradient centrifugation with Histopaque-1083 (Sigma-Aldrich Co.); then, cells were seeded on 4-well chamber slides, coated with rat vitronectin, and cultured in 5% fetal bovine serum (FBS)/EBM-2 medium supplemented with growth factors (SingleQuot Kit; Clonetics Corp., San Diego, CA, USA). After 4 days in culture, cells were incubated with DiI-acLDL (Biomedical Technologies, Inc., Stoughton, MA, USA) for 1 hour and stained with FITC-conjugated BS-1 lectin (Vector Laboratories, Burlingame, CA, USA), and then the slides were viewed with a Carl Zeiss Axio Observer.D1 and Image J™ software (NIH, USA). Double-stained cells were considered EPCs and counted in 3 wells, 10 randomly selected HPFs per well.

To determine the number of monocytes/macrophages present in the peripheral circulation, mononuclear cells were isolated from 500 μL of peripheral blood via a gradient centrifugation, seeded on 4-well chamber slides, and cultured in RPMI 1640 medium containing 10% heat-inactivated FBS. After 4 days in culture, cells were sequentially incubated with anti-CD68 antibodies (AbD Serotec), Alexa Fluor 555 goat anti-rat IgG secondary antibodies (Invitrogen Corporation), and FITC-conjugated isolectin B4 (Vector Laboratories), and then the slides were viewed with a Carl Zeiss Axio Observer.D1 and Image J™ software (NIH, USA). Cells stained positively for CD68 expression were considered macrophages, and cells stained positively for both CD68 and isolectin B4 were considered activated macrophages; the identified cells were counted in 3 wells, 10 HPFs per well.

Additional cell populations {#S19}
---------------------------

Primary isolates of dermal fibroblasts, bone marrow--derived macrophages, and 3T3 fibroblasts were obtained and cultured as summarized in the [Supplemental Methods](#SD1){ref-type="supplementary-material"}.

Cell functional assays {#S20}
----------------------

Migration was evaluated via a modified Boyden\'s chamber assay, proliferation was evaluated via the CellTiter 96 nonradioactive cell proliferation assay (Promega Corporation, Madison, WI, USA), and phagocytosis was evaluated via the CytoSelect™ 96-well phagocytosis assay (red blood cell, colorimetric format; Cell Biolabs, Inc., San Diego, CA, USA) as directed by the manufacturer\'s instructions. The protocols are summarized in the [Supplemental Methods](#SD1){ref-type="supplementary-material"}.

Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) {#S21}
--------------------------------------------------------------------------------

Quantitative RT-PCR analyses were performed via standardized protocols as summarized in the [Supplemental Methods](#SD1){ref-type="supplementary-material"} and normalized to endogenous 18S rRNA expression. Primer and probe sequences are listed in [Table S1](#SD1){ref-type="supplementary-material"}.

Statistical analyses {#S22}
--------------------

All results are presented as mean ± SEM. Comparisons between 2 groups were evaluated with the Student\'s *t*-test, and comparisons among 3 or more groups were evaluated via one-way ANOVA followed by post-hoc testing with the Tukey procedure. A *P* value of less than 0.05 was considered statistically significant.

Supplementary Material {#SM}
======================

Supplemental Methods

Wound model and treatment

All surgical procedures were performed in accordance with the American Heart Association\'s Guidelines for Animal Use and were approved by the Institutional Animal Care and Use Committee of Northwestern University. Cutaneous wounds were created as described previously ([@R3]; [@R4]; [@R19]; [@R28]). Briefly, mice were anesthetized with an intraperitoneal injection of ketamine (90-120 mg/kg) and xylazine (5-10 mg/kg) or with 2-4% isoflurane, then the dorsal surface was shaved, washed with povidone-iodine solution and alcohol, and a disposable skin punch biopsy tool (0.8-cm diameter) (Acuderm Inc., Fort Lauderdale, FL, USA) was used to create one full-thickness excisional skin wound (extending down to the fascia) on the dorsal surface. Immediately after wounding, 6 mg/kg AMD3100 octahydrochloride (Sigma-Aldrich Co., St. Louis, MO, USA) in 30 μL saline or saline alone was topically applied to the wound bed, and then a semipermeable transparent dressing (Tegaderm; 3M Health Care, St. Paul, MN, USA) was placed over the wound, secured to the surrounding skin and muscle with 6-0 Prolene sutures, and left in place until subsequent evaluations were performed (i.e., for up to 14 days after wounding). Mice were kept on a heating pad until fully recovered from the anesthesia.

Additional cell populations

Primary isolates of dermal fibroblasts were harvested from 6- to 8-week-old db/db mice as previously described ([@R3]; Lerman *et al.*, 2003). Mice were sacrificed, and trunk skin was removed by sharp dissection; special care was taken to remove the underlying adipose tissue before culture. The harvested skin was minced and digested with 0.20% collagenase I solution (Sigma-Aldrich Co.) in serum-free Dulbecco\'s modified Eagle\'s medium (DMEM, Mediatech, Inc., Manassas, VA, USA) at 37°C for 2 hours, then the dissociated cells were isolated by centrifugation, resuspended in DMEM culture medium containing 10% FBS and 1% antibiotic/antimycotic solution (100 U/ml penicillin and 100 μg/ml streptomycin; Mediatech, Inc.), and cultured under 5% CO~2~ at 37°C and 100% humidity; the culture medium was refreshed every other day. Cells were passaged before attaining confluence, and experiments were performed after 5-10 passages.

Bone marrow--derived macrophages were cultured as described previously ([@R4]; [@R28]; Maruyama *et al.*, 2005). Total MNCs were isolated from the tibias and femurs of 8- to 10-week-old female db/db mice by gradient centrifugation with Histopaque-1083 (Sigma-Aldrich Co.). The isolated MNCs were plated on cell-culture dishes at a density of 5×10^5^ cells/cm^2^ and cultured under 5% CO~2~ at 37°C and 100% humidity for 4 days; then, the nonadherent cells were removed and the adherent cells were reseeded at a density of 5×10^4^ cells/cm^2^ and cultured for 3 additional days. The culture medium consisted of RPMI 1640 medium (Lonza Group Ltd, Basel, Switzerland) containing 10% heat-inactivated FBS (Sigma-Aldrich Co.), 1×10^--5^ mol/L 2-mercaptoethanol (Sigma-Aldrich Co.), 10 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Sigma-Aldrich Co.), 0.1 mmol/L nonessential amino acids (Lonza Group Ltd), 1 mmol/L sodium pyruvate (Lonza Group Ltd), 1% antibiotic/antimycotic solution (100 U/ml penicillin and 100 μg/ml streptomycin, Mediatech, Inc.), and 10 ng/mL of recombinant mouse macrophage colony stimulating factor (mMCSF) (R&D Systems Inc., Minneapolis, MN, USA) (Fogg *et al.*, 2006; Gersuk *et al.*, 2008; [@R28]). Cells were used for in vitro experiments after 3 to 5 passages.

3T3 fibroblasts were obtained from ATCC (Manassas, VA, USA) and cultured in DMEM culture medium containing 10% FBS and 1% antibiotic/antimycotic solution (100 U/ml penicillin and 100 μg/ml streptomycin; Mediatech, Inc.) at 5% CO~2~, 37°C, and 100% humidity; the culture medium was refreshed every other day.

Cell migration

Cell migration was evaluated as described previously ([@R3]; [@R4]) via a modified Boyden\'s chamber assay. Briefly, a polycarbonate filter (5-μm pore size) (GE Infrastructure, Fairfield, CT, USA) was inserted between the upper and lower chambers, and cell suspensions (5×10^4^ cells/well) were placed in the upper chamber; the lower chamber was filled with medium containing AMD3100 (0 or 2 μg/mL) or mouse recombinant platelet-derived growth factor BB (PDGF-BB) (50 ng/mL) (BioVision, Inc., Mountain View, CA, USA). Assays with fibroblasts isolated from db/db mice were performed in 5 mmol/L or 25 mmol/L D-glucose, or in 25 mmol/L D-mannitol to serve as an osmotic control for the high-glucose condition. The chamber was incubated for 20 hours at 37°C and 5% CO~2~, and then the number of cells that had migrated to the lower chamber were counted in 5 HPFs (40× magnification) per chamber. Assays were performed in triplicate, and migration was reported as the mean number of migrated cells per HPF.

Proliferation assay

Cell proliferation was evaluated as described previously ([@R3]; [@R4]) via the CellTiter 96 nonradioactive cell proliferation assay (Promega Corporation, Madison, WI, USA) as directed by the manufacturer\'s instructions. Briefly, subconfluent cells were seeded (fibroblasts: 5×10^3^ cells/well; EPCs or macrophages: 10^4^ cells/well) on 96-well, flat-bottomed plates with 100 μL of growth medium; then, the cells were treated with AMD3100 (0, 2, or 10 μg/mL) or basic fibroblast growth factor (bFGF) (50 ng/mL) (R&D Systems Inc.) and incubated for 50 hours at 37°C. Assays with fibroblasts isolated from db/db mice were performed in 5 mmol/L or 25 mmol/L D-glucose, or in 25 mmol/L D-mannitol to serve as an osmotic control for the high-glucose condition. Absorbance at 490-nm wavelength was recorded with a 96-well ELISA plate reader (Bionetics Laboratory, Kensington, MD). Assays were performed in triplicate, and proliferation was reported as mean absorbance per well.

Phagocytosis assay

Macrophage phagocytosis was evaluated via the CytoSelect™ 96-well phagocytosis assay (red blood cell, colorimetric format; Cell Biolabs, Inc., San Diego, CA, USA) as directed by the manufacturer\'s instructions. Briefly, subconfluent cells were seeded on 96-well (10^4^ cells/well), flat-bottomed plates with 100 μL of culture medium, incubated overnight at 37°C, 5% CO~2~, treated with AMD3100 (0 or 2μg/mL), and then incubated for 24 hours. IgG opsonized erythrocyte suspension (washed and preserved sheep red blood cells, 10% suspension; MP Biomedicals, Solon, OH, USA) was added to each well and incubated for 1 hour; then, the non-phagocytosed erythrocytes were removed, and the remaining cells were washed with PBS and incubated with cell-lysis buffer and substrate solution. The prepared cell lysate was examined via a colorimetric detection method; absorbance at 630-nm wavelength was recorded with a 96-well ELISA plate reader (Bionetics Laboratory). Assays were performed in triplicate, and phagocytosis was reported as mean absorbance per well.

Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR)

RNA was isolated as described previously ([@R3]; [@R4]; [@R28]) from homogenized skin samples or from 8×10^5^ cells per experimental condition by using RNA-Stat (Tel-Test, Inc., Friendswood, TX, USA) as directed by the manufacturer\'s instructions. Total RNA was reverse transcribed with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA), and amplification was performed on a Taqman 7300 (Applied Biosystems, Foster City, CA, USA); primer and probe sequences are listed in the Supplemental Table. The PCR procedure consisted of a 2-minute hold at 50°C, then a 10-minute hold at 95°C followed by 40 2-step cycles between 95°C for 15 seconds and 60°C for 60 seconds. Relative mRNA expression was calculated with the comparative CT method (relative expression=2^ΔCT^) and normalized to the expression of the endogenous 18S gene.
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BS1-lectin

:   Bandeiraea simplicifolia lectin 1

CXCR4

:   CXC-chemokine receptor 4

DAPI

:   4\',6-diamidino-2-phenylindole

DiI-acLDL

:   DiI-labeled acetylated low density lipoprotein

EPC

:   endothelial progenitor cell

HPF

:   high-power field

PDGF

:   platelet-derived growth factor

PDGFR

:   platelet-derived growth-factor receptor

SDF-1

:   stromal-cell-derived factor 1

αSMA

:   smooth-muscle α-actin

![Wound-healing in diabetic mice\
Full-thickness, excisional skin wounds were created on the backs of genetically diabetic (leptin receptor--deficient) mice, treated with 6 mg/kg AMD3100 in 30 μL saline or saline alone, then examined 0, 7, and 14 days later. (**A**) Wounds were digitally photographed, and (**B**) the extent of wound closure was expressed as the percentage decline in wound area. (**C**) Epithelialization, (**D**) granulation, and (**E**) inflammation scores ranging from 1 (little or none) to 5 (extensive or severe) were assigned to sections of hematoxylin and eosin--stained wound tissue harvested 14 days after treatment. Scores were summarized as the mean±SEM for each treatment group. (**F**) Representative sections of wound tissue harvested 14 days after treatment; the boxed regions in the upper panels (50× magnification) are displayed at higher magnification (200× magnification) in the lower panels. Functional blood vessels are identified with arrows. Bar=100 μm.](nihms-330241-f0001){#F1}

![Collagen formation, vascularity, and monocyte/macrophage infiltration at the wound site\
Collagen formation, vascularity, and monocyte/macrophage infiltration were evaluated 14 days, 14 days, and 7 days, respectively, after wounds were treated with 6 mg/kg AMD3100 in 30 μL saline or saline alone. (**A, B**) Collagen formation was assessed in sections of wound tissue stained with Masson trichrome or picrosirius red; picosirius red stain accentuates the birefringence of collagen fibers when viewed under polarized light. The boxed regions in the Masson-trichrome--stained panels (left) are displayed with picrosirius red staining in the right panels. Bar=100 μm. (**B**) Fiber formation at the wound center was quantified as the percentage of the digitized image area that fluoresced red (mature fibers) or yellow-green (immature fibers). (**C**) Wound tissue sections were stained with FITC-conjugated BS1 lectin (green) to identify endothelial tissue and with alkaline-phosphatase αSMA (red) to identify smooth-muscle cells. αSMA-positive vessels are identified with arrows. Bar=100 μm. (**D**) Capillary density was quantified as the percentage of the image area that fluoresced positively for BS1 lectin, and (**E**) smooth muscle--containing vessels were quantified as the number of structures in the dermis that stained positively for both BS1 lectin and αSMA. (**F**) Sections of wound tissue were stained for expression of the monocyte/macrophage marker CD68 (red); nuclei were counterstained with DAPI (blue); bar=100 μm. The boxed regions were evaluated for quantification of (**G**) monocyte/macrophage infiltration (i.e., the number of CD68-positive cells).](nihms-330241-f0002){#F2}

![mRNA expression at the wound site\
The expression of (**A**) CD68, (**B**) SDF-1α, and (**C**) PDGF-B in wound tissues was assessed 7 and 14 days after wounds were treated with 6 mg/kg AMD3100 in 30 μL saline or saline alone; measurements were performed via quantitative real-time RT-PCR and normalized to 18S rRNA expression.](nihms-330241-f0003){#F3}

![Mobilization of bone marrow--derived cells\
The number of EPCs and macrophages in the peripheral blood was determined 7 days after wounds were treated with 6 mg/kg AMD3100 in 30 μL saline or saline alone. (**A**) Mononuclear cells were isolated from 500 μL of peripheral blood, then incubated with DiI-acLDL (red) and stained with FITC--conjugated BS1 lectin (green), or stained for the expression of CD68 (red) and isolectin B4 (green); nuclei were counterstained with DAPI (blue). Bar=100 μm. (**B**) EPC counts were quantified as the number of cells stained positively for both DiI-acLDL and BS-1 lectin, total macrophage counts were quantified as the number of cells stained positively for CD68, and activated macrophages were quantified as the number of cells stained positively for both CD68 and isolectin B4.](nihms-330241-f0004){#F4}

![Activity of diabetic mouse fibroblasts, macrophages, and EPCs\
(**A, B**) Fibroblast migration toward 0 μg/mL and 2 μg/mL AMD3100 or 50 μg/mL PDGF-BB (positive control) was evaluated via a modified Boyden\'s chamber assay in 5 mmol/L or 25 mmol/L D-glucose, or in 25 mmol/L D-mannitol to serve as an osmotic control for the high-glucose condition. Bar=100 μm. (**C**) Fibroblasts were treated with or without 2 μg/mL or 10 μg/mL AMD3100, or with 50 μg/mL basic fibroblast growth factor (bFGF, positive control), for 50 hours, and then fibroblast proliferation was evaluated via the CellTiter 96 nonradioactive cell proliferation assay in 5 mmol/L or 25 mmol/L D-glucose, or in 25 mmol/L D-mannitol to serve as an osmotic control for the high-glucose condition. (**D**) EPC proliferation, macrophage proliferation, and macrophage phagocytosis activity were assessed after treatment with or without 2 μg/mL AMD3100 for 50 (proliferation) or 24 (phagocytosis) hours; proliferation was assessed via the CellTiter 96 nonradioactive cell proliferation assay, and phagocytosis was assessed via the CytoSelect™ 96-well phagocytosis assay (red blood cell, colorimetric format).](nihms-330241-f0005){#F5}

![Activity and mRNA expression in 3T3 fibroblasts after treatment with AMD3100\
(**A**) The migration of 3T3 fibroblasts toward 2 μg/mL AMD3100 was evaluated via a modified Boyden\'s chamber assay. (**B**) 3T3 fibroblasts were treated with or without 2 μg/mL AMD3100 for 48 hours, then proliferation was evaluated via the CellTiter 96 nonradioactive cell proliferation assay. (**C**) 3T3 fibroblasts were treated with or without 2 μg/mL AMD3100 for 6 or 12 hours; then, the mRNA expression of SDF-1α, PDGF-B, and monocyte chemotactic protein-1 (MCP-1) was assessed via quantitative real-time RT-PCR and normalized to 18S rRNA expression.](nihms-330241-f0006){#F6}
